| 10.28 0.11 (1.08%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.08  |
1-year : | 13.93 |
| Resists | First : | 11.2 |
Second : | 11.93 |
| Pivot price | 10.78 |
|||
| Supports | First : | 10.02 | Second : | 8.33 |
| MAs | MA(5) : | 10.5 |
MA(20) : | 10.97 |
| MA(100) : | 12.38 |
MA(250) : | 12.18 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 20.4 |
| RSI | RSI(14): 33.8  |
|||
| 52-week | High : | 14.56 | Low : | 9.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FOLD ] has closed above bottom band by 22.3%. Bollinger Bands are 5.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.32 - 10.39 | 10.39 - 10.45 |
| Low: | 9.96 - 10.04 | 10.04 - 10.11 |
| Close: | 10.17 - 10.28 | 10.28 - 10.38 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Tue, 23 Apr 2024
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? - Simply Wall St
Fri, 19 Apr 2024
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? - Yahoo Finance
Fri, 12 Apr 2024
Amicus Therapeutics Becomes Oversold (FOLD) - Nasdaq
Wed, 03 Apr 2024
Amicus Therapeutics CEO sells shares worth $87,495 By Investing.com - Investing.com
Wed, 27 Mar 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough - Simply Wall St
Sat, 02 Mar 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 295 (M) |
| Shares Float | 222 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 109.9 (%) |
| Shares Short | 32,490 (K) |
| Shares Short P.Month | 30,910 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | -38 % |
| Operating Margin | -3.3 % |
| Return on Assets (ttm) | -6.2 % |
| Return on Equity (ttm) | -107.1 % |
| Qtrly Rev. Growth | 30.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.35 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -20.16 |
| PEG Ratio | 0 |
| Price to Book value | 18.69 |
| Price to Sales | 7.6 |
| Price to Cash Flow | -43.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|